Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Non-Current Deffered Revenue (2017 - 2024)

Ligand Pharmaceuticals (LGNDZ) has disclosed Non-Current Deffered Revenue for 12 consecutive years, with $2.2 million as the latest value for Q4 2024.

  • Quarterly Non-Current Deffered Revenue rose 55.54% to $2.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2024, up 55.54% year-over-year, with the annual reading at $2.2 million for FY2024, 55.54% up from the prior year.
  • Non-Current Deffered Revenue hit $2.2 million in Q4 2024 for Ligand Pharmaceuticals, down from $2.5 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $9.3 million in Q4 2021 to a low of $44000.0 in Q4 2022.
  • Historically, Non-Current Deffered Revenue has averaged $3.8 million across 4 years, with a median of $2.7 million in 2024.
  • Biggest five-year swings in Non-Current Deffered Revenue: crashed 99.53% in 2022 and later surged 3181.82% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $9.3 million in 2021, then plummeted by 99.53% to $44000.0 in 2022, then soared by 3181.82% to $1.4 million in 2023, then soared by 55.54% to $2.2 million in 2024.
  • Business Quant data shows Non-Current Deffered Revenue for LGNDZ at $2.2 million in Q4 2024, $2.5 million in Q3 2024, and $2.7 million in Q2 2024.